ALTEOGEN Inc (196170)
KOSDAQ · Korea · prices in KRW · close of 27 Oct 2026
Key indicators
| Last close | KRW 218,500.00 |
|---|---|
| 52-week range | 209,000.00 – 569,000.19 |
| Return, 1 month / 3 months | −12.6% / −9.0% |
| Return, 1 year / 3 years | −41.2% / +373.8% |
| Trend | Below its 200-day average |
| RSI (14) | 36 |
| Volatility (1 year) | 72.9% |
| Worst drawdown (1 year) | -52.0% |
| Average daily value traded | 137,034.61M KRW |
| Dividend yield | 0.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Alteogen is a South Korean biopharmaceutical company that develops protein-based medicines and the technology platforms used to make them. Its work centres on long-acting versions of protein drugs, including antibody treatments, and on biosimilar products. The company serves the pharmaceutical and biotechnology industry through partnerships and licensing of its platform technologies, and it is based in Korea, where it carries out research and development of its product candidates.
On this site ALTEOGEN Inc appears as a stock on the KOSDAQ (Korea), code 196170, with prices in South Korean won (KRW). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
ALTEOGEN Inc (196170) trades on the KOSDAQ in Korea. It last closed at KRW 218,500.00 on 27 October 2026.
Its price-based Market X-Ray is 51 out of 100 (a fair price profile), ranking 902 of 1,833 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 41.2% and over the last three months it fell 9.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on KOSDAQ
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 48 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -22.1% | ||
| From 52-week high | -60.9% | ||
| Momentum | 43 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -9.0% | ||
| 6-month return | -25.1% | ||
| 12-month return, skipping the last month | -32.7% | ||
| Stability (higher is calmer) | 53 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 72.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -52.0% | ||
| Liquidity | 100 · Strong | Trades actively. | |
| Average daily value traded | 137,034.61M KRW | ||
| Zero-volume days | 0.0% | ||
| Income | 3 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.2% | ||
| Years with dividends | 1 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | −5.4% |
|---|---|
| 1 month | −12.6% |
| 3 months | −9.0% |
| 6 months | −25.1% |
| 1 year | −41.2% |
| 3 years | +373.8% |
| 5 years | +370.5% |
Signals
| 50-day / 200-day average | 269,120.00 / 280,533.14 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 12,798.65 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 Dec 2025 | KRW 371.0001 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on KOSDAQ; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.